Hormone Tx no harm after nonserous epithelial ovarian CA

April 10, 2016

(HealthDay)—For women with nonserous epithelial ovarian cancer, hormone therapy (HT) after treatment does not reduce survival, according to a study published in the May issue of Obstetrics & Gynecology.

Laura Power, M.D., from the University of Manitoba in Winnipeg, Canada, and colleagues conducted a retrospective cohort study to examine the correlation between HT after nonserous epithelial ovarian cancer and overall and disease-free survival. Women with known nonserous epithelial ovarian, fallopian tube, or primary peritoneal cancer between 1995 and 2010 who had used HT after treatment were identified.

The researchers found that 94 received HT after treatment and 263 did not. In multivariate landmark analysis and time-varying Cox regression analysis, disease-free survival was improved in HT users younger than 55 years of age (adjusted hazard ratios, 0.354 and 0.212) after adjustment for International Federation of Gynecology and Obstetrics stage and need for chemotherapy. No significant difference was seen for overall survival in this age group. For women aged 55 years and older there were no correlations for HT use and overall or disease-free survival.

"After treatment for nonserous , is not associated with decreased disease-free or overall survival," the authors write.

Explore further: Surgery, chemo best for elderly with advanced ovarian cancer

More information: Full Text (subscription or payment may be required)

Related Stories

Surgery, chemo best for elderly with advanced ovarian cancer

December 29, 2015
(HealthDay)—Primary debulking surgery and chemotherapy in an optimal timeframe is associated with the longest survival time for elderly women with advanced ovarian cancer, according to a study published in the January issue ...

Survival improving for women with ovarian cancer

May 12, 2015
(HealthDay)—Women diagnosed with ovarian cancer are now much more likely to survive the disease than they were several decades ago, according to research published online May 6 in Obstetrics & Gynecology.

Timing of hormone therapy use impacts alzheimer's risk

October 25, 2012
(HealthDay)—Use of hormone therapy (HT) within five years of menopause is associated with a reduction in the risk of Alzheimer's disease (AD), according to a study published online Oct. 24 in Neurology.

VTE risk varies by hormone therapy formulation

September 18, 2012
(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin ...

Novel pharmacological activity for R-ketorolac in ovarian cancer

August 4, 2015
(HealthDay)—The R-enantiomer of ketorolac is enriched in peritoneal fluids and inhibits peritoneal cell GTPase activity with administration after ovarian cancer surgery, according to a study published online June 12 in ...

Gene tests may help predict outcomes in advanced ovarian cancer

March 21, 2016
(HealthDay)—A special genetic test might help gauge outcomes for women diagnosed with ovarian cancer, a new study suggests.

Recommended for you

New study reveals time and day women are most likely to give birth

June 15, 2018
A new study has found that the time and day that women give birth can vary significantly depending on how labour starts and the mode of giving birth.

Blood test for pregnant women can predict premature birth

June 7, 2018
A new blood test for pregnant women detects with 75-80 percent accuracy whether their pregnancies will end in premature birth. The technique can also be used to estimate a fetus's gestational age—or the mother's due date—as ...

Drug combination offers more effective care for patients suffering miscarriage

June 6, 2018
A combination of the drugs mifepristone and misoprostol can help bring closure to some women and their families suffering from miscarriage, and reduces the need for surgical intervention to complete the painful miscarriage ...

Genes, environment and schizophrenia—new study finds the placenta is the missing link

May 28, 2018
Hiding in plain sight, new research shines a spotlight on the placenta's critical role in the nature versus nurture debate and how it confers risk for schizophrenia and likely other neurodevelopmental disorders including ...

Vendors say pot eases morning sickness. Will baby pay a price?

May 22, 2018
(HealthDay)—Nearly 70 percent of Colorado marijuana dispensaries recommended pot products to manage early pregnancy-related morning sickness, new research reveals.

Pregnancy drug DES might have triggered ADHD in the grandchildren of women who used it

May 21, 2018
A study conducted by researchers at Columbia University's Mailman School of Public Health and Harvard T.H. Chan School of Public Health reported elevated odds for attention deficit hyperactivity disorder (ADHD) in the grandchildren ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.